Recent Security Class Actions

On April 19, 2024, Rivian Automotive, Inc. was sued for violations of the federal securities laws in the United States District Court for the Central District of California on behalf of investors who purchased or otherwise
acquired Rivian securities between March 1, 2023 and February 21, 2024, both dates inclusive (the “Class Period”).

On April 17, 2024, AST SpaceMobile, Inc. was sued for violations of the federal securities laws in the United States District Court for the Western District of Texas on behalf of investors who purchased or otherwise acquired SpaceMobile securities between November 14, 2023 and April 1, 2024, inclusive (the “Class Period”).

On April 17, 2024, Doximity, Inc. was sued for violations of the federal securities laws in the United States District Court for the Northern District of California on behalf of investors who purchased or otherwise acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”).

On April 16, 2024, Perion Network Ltd. was sued for violations of the federal securities laws in the United States District Court for the Southern District of New York on behalf of investors who purchased, or otherwise acquired, Perion common stock during the period from February 9, 2021 through April 5, 2024, inclusive (the “Class Period”).

On April 12, 2024, VinFast Auto Ltd. was sued for violations of the federal securities laws in the United States District Court for the Eastern District of New York on behalf of investors who purchased or otherwise acquired VinFast securities: (a) pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the merger (“Merger”) consummated on August 14, 2023 by and among the Company, Black Spade, and Nuevo Tech Limited, a Cayman Islands exempted company and wholly owned subsidiary of the Company (“Merger Sub”); and/or (b) between August 15, 2023 and January 17 2024, both dates inclusive (the “Class Period”).

On April 12, 2024, QuidelOrtho Corporation was sued for violations of the federal securities laws in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired QuidelOrtho common stock between February 18, 2022 and April 1, 2024, inclusive (the “Class Period”).

On April 11, 2024, Sonder Holdings Inc. was sued for violations of the federal securities laws in the United States District Court for the Central District of California on behalf of investors who purchased or otherwise acquired publicly traded Sonder securities between March 16, 2023 and March 15, 2024, both dates inclusive (the “Class Period”).

On April 11, 2024, Ocugen Inc. was sued for violations of the federal securities laws in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased or otherwise acquired publicly traded Ocugen securities between May 8, 2020 and April 1, 2024, inclusive (the “Class Period”).

According to the Complaint, Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the U.S. and internationally. Checkpoint’s lead antibody product candidate is cosibelimab for the treatment of selected recurrent or metastatic cancers, including metastatic cSCC and locally advanced cSCC. The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Checkpoint had overstated its oversight of, and/or its establishment of adequate manufacturing standards and controls over, its third-party contract manufacturers; (ii) accordingly, there were one or more issues with the Company’s third-party contract manufacturing organization (“CMO”) for cosibelimab; (iii) all the foregoing reduced the likelihood that the FDA would approve the cosibelimab BLA in its present form; (iv) as a result, the manufacturing, regulatory, and commercial prospects of cosibelimab were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On April 5, 2024, Checkpoint Therapeutics, Inc. was sued for violations of the federal securities laws in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”).